This trial is active, not recruiting.

Condition lung cancer
Sponsor Taipei Medical University WanFang Hospital
Start date March 2008
End date January 2010
Trial size 91 participants
Trial identifier NCT01140958, Pharmacoeconomic-01


Lung cancer is the No. cause of cancer death in Taiwan. Yet most of lung cancer are diagnosed at late stage, not amenable to surgical resection. With the introduction of new targeted agents, such as EGFR tyrosine kinase inhibitors and the identification of EGFR mutations, lung cancer management has markedly changed in recent years. However, these new agents are costly and their payment is restricted in certain situations defined National Insurance Agency. Therefore, using databases from National Insurance Agency might not be able to reflect the exact impact on pharmacoeconomics. In this study, the investigators will analyze the data from a tertiary medical center, where all the costs including insurance reimbursement, co-payment, and payment not covered by insurance. The investigators will also compare with the investigators results with national database to analyze the cost benefit of these new agents on lung cancer.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective retrospective

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: - lung cancer patients in WanFang Hospital Exclusion Criteria: - non

Additional Information

Official title A Retrospective Pharmacoeconomic Study of Lung Cancer in Wan-Fang Hospital
Principal investigator Hsin-Gjin Eugene Liu
Trial information was received from ClinicalTrials.gov and was last updated in June 2010.
Information provided to ClinicalTrials.gov by Taipei Medical University WanFang Hospital.